{
    "nctId": "NCT00516243",
    "briefTitle": "Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer",
    "officialTitle": "Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "MTD defined as the dose that causes 25% DLT assessed using NCI CTCAE version 3.0",
    "eligibilityCriteria": "Criteria:\n\n* History of histologically confirmed stage I, II, or III breast carcinoma without evidence of disease at study entry\n* No evidence of recurrent disease (patients with resected local recurrence are eligible)\n* Normal mammogram of the contralateral breast within the past 12 months, defined as no new suspicious calcifications or other abnormal findings warranting a breast biopsy\n* No history of histologically confirmed bilateral breast cancer\n* No evidence of metastatic breast cancer\n* Registered in the outpatient medical oncology clinic at Columbia University Medical Center (CUMC), MD Anderson Cancer Center (MDACC), Memorial Sloan Kettering Cancer Center (MSKCC), or the Weill-Cornell campus of New York Presbyterian Hospital (NYP-WC)\n* Hormone receptor status: Estrogen- and progesterone-receptor negative\n* Menopausal status: Pre- or postmenopausal\n* ECOG performance status \\< 2 (Karnofsky \\> 60%)\n* Leukocytes \\>= 3,000/uL\n* Absolute neutrophil count \\>= 1,500/uL\n* Platelets \\>= 100,000/uL\n* Total bilirubin within normal institutional limits\n* AST/ALT =\\< 2.5 times institutional upper limit of normal\n* Serum creatinine within normal institutional limits\n* Not pregnant or nursing\n* Negative pregnancy test\n* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extract (Polyphenon E), such as green tea food products or supplements containing EGCG\n* No history of gastrointestinal bleeding including, but not limited to, any of the following: Diverticulosis; Peptic ulcer disease; Erosive gastritis; Varices\n* No uncontrolled or significant co-morbid illness including, but not limited to, any of the following: active or serious infection requiring intravenous antibiotics; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; active gastrointestinal bleeding; active liver disease; psychiatric illness/social situations that would limit compliance with study requirements\n* No active malignancy, except for squamous cell carcinoma of the skin; basal cell carcinoma of the skin; carcinoma in situ; stage IA or IB invasive squamous cell carcinoma of the cervix treated by surgery and/or radiation therapy; or stage IA grade 1 adenocarcinoma of the endometrium treated by surgery\n* At least 6 months since prior chemotherapy, radiation therapy, and/or breast surgery\n* No prior radiation therapy or implant in the contralateral breast\n* More than 30 days since prior and no concurrent medications, herbs, or vitamin and mineral supplements that contain tea compounds or caffeine\n* At least 30 days since prior and no other concurrent investigational agents\n* At least 30 days since prior and no concurrent tea consumption\n* Willing to limit regular coffee consumption to =\\< three 8-ounce cups per day for 30 days prior to baseline evaluation and during the study intervention\n* Total daily caffeine consumption should not exceed 375 mg/day\n* No concurrent hormone replacement therapy, tamoxifen, or raloxifene\n* Concurrent oral contraceptives allowed provided the dose has not been changed for at least 6 months prior to study entry\n* No concurrent chemotherapy or radiation therapy",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}